{"name":"Crossbow Therapeutics, Inc.","slug":"crossbow-therapeutics-inc","ticker":"","exchange":"","domain":"crossbow.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOT0lITjRuVGZfV0w0dS1NLV9TT01mZTYtSWt1XzZ0WWd3eVJ3NzFYN1Uwa25vOHZoWGhXb053aTJ4R0htZHFMSjhjYUpOMmNNc2VhYUNYTVNiQ3lpV25tNS1NUVF6ZldXNzctTDRuNkVXTWNIYW5ld0NzdnZMRGNZZ29SOUQ3WFROZE44YWZKR2FGbTdZY3R3WkQxTHBiaXZYTG15Ump3Yl9HRHJLMjR2TmhvNTFGenc1T3JLOFAzTUZDaThGWW5ZRWNSV0lMdkU2dTgxRGx6U2hPUnZZUHlMX19TM1ZQRGp5bkRfWDNrM0NxbVBab1g1cGtXRXVfOGk4QzB1MWpVWHpDRWNiS3F6eHAwZGhBYk5WVndUbG9HUQ?oc=5","date":"2026-03-18","type":"pipeline","source":"Business Wire","summary":"Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer - Business Wire","headline":"Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNTlZIR3Z3Q1dqaDJ2NXV0bTRCUlJtMXlRUktNWi1wejJHaXpmTDZPc0tmUWgwSVVldUtrWXM5ZzZMU0NmR3NUb0lTZmh3M21XODlxRUtydWRlejl3YWwxckhJbGdfeXlLUWhwaGI3dG82Z3ptbWFnbzhRd2NsUFhBeDJxbk1VeFRQbWRQbjBmZzVlR1RZdzNEOUdB?oc=5","date":"2026-03-18","type":"pipeline","source":"Fierce Biotech","summary":"Crossbow hits $77M series B round to bankroll quiver of T-Bolts - Fierce Biotech","headline":"Crossbow hits $77M series B round to bankroll quiver of T-Bolts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPTTRkMHJiRnRJY2hIa09KTEVRZURZN0UwcjBzTC1JeDl3anlxRmZ1d3pLRm9jM21MUk5uY21ocUJXWXo4aFZiV0h0bi1oMWxVN28tdFY2VERMNVkxNFJ3ZTVKM1J3ZVk5eDZUWlk0eC1OU0M4ZnJfbWtSUnRBemVuanZmSkNwM0JUYk1USXJQdndlZjVuZ3lXcjg0QXRSU0ZRSWhrLXpLc2hJeXgzX2J6N3dKWnRmb25Ic0JUOGRIUmhpRUl1YTVGV1BzUGc4TlRFeHdXQlpDTVpaa0NpTEVsd2NxcHJJNURjdlE?oc=5","date":"2026-03-18","type":"pipeline","source":"Pharmaceutical Executive","summary":"Pharma Funding Roundup: Excalipoint Therapeutics Completes $68.7 Million Seed Finance Round, Crossbow Therapeutics Raises $77 Million in Series B Financing - Pharmaceutical Executive","headline":"Pharma Funding Roundup: Excalipoint Therapeutics Completes $68.7 Million Seed Finance Round, Crossbow Therapeutics Raise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPTlZDY016VmFxVURrLWlQR0JnbzFNaXJtd3J3aHVfR2YtOWhuR2VRdURjVkFGN2RlNm9SYmNoNHlGcy1idms1RVE5cWtscVBwV3huMjJvekZua1BEWjExbHpXcWlGRURDOVlrYU1teUdIbXRVZVlRY2dhTDlLSXBRUmdQa1RLM3V3?oc=5","date":"2026-03-18","type":"pipeline","source":"The Business Journals","summary":"Cambridge biotech led by former AstraZeneca exec secures $77M - The Business Journals","headline":"Cambridge biotech led by former AstraZeneca exec secures $77M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOR3BmamNvYkJJOXJYVzRENGhfenNhbXZwT2ttNUlzalVhT3NTNGZ0QzAyUXFpZUZCQmdfTmQ0YnNYelhybzVDd2lJNGl6UFRiOW9DQnN4NThUQ2c1MHBnaFJDNHZYUHR3Vkx2amVsajlGMWRVczdFM0V1NTRwbjVCUnBfd1lIc01vNUdHa0FhbERfTU1F?oc=5","date":"2026-03-18","type":"trial","source":"Endpoints News","summary":"Briggs Morrison’s Crossbow unveils $77M Series B for T cell engagers - Endpoints News","headline":"Briggs Morrison’s Crossbow unveils $77M Series B for T cell engagers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPV2Q4OEh5dnFYY0lJa3hTdlNoVkdNalZTM2l3MEhYZlliTFRxSzcybEZ2Uk1sc3dkdkFuYTZ5T1B2VlpUM2d1eF81R3ZWZ3NXa25FbWZORkRuaVFlSGpyaWtKcWdjTzJvbnpqbU5CVXZ0M0ZkVTMtSTByZng1LW1fd0Vxb1VHb1h5OUVONVFVZ244ZndDUFE2ZzhkZkVhZ3JvVEFEc0lmU1BDcEMyaHRaZkJMQW1SVmhob0JSQ0hrMWxlTnhxcEJoRXV0eHFvQ1hwTkhheGVndkF4c205UGVXZ1N3d2NWUQ?oc=5","date":"2025-09-16","type":"trial","source":"Business Wire","summary":"Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies - Business Wire","headline":"Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxOMlZiYXFQU1IyN04yTDNYRjRFOWxMSGZSaHduNnVUcFc5YjhRX01tRjZpdDVxSmQ3NGRSWTZGVW1zaEtDVE5hbG5LaDVxTWhyeGd5bmNLMGhubWd5ajhYZHVDTFlHUG9qWmFFeG9TMmNVNTZCVTFrRnFrWEY2YVA2VVFvNjhmNDVnazBaVTd0UlJVRU1NX3VGUWc1Um9wUG5qenNZaGprdkR4WE8ySkhqQmxCbmNab1EyQ0RxTlRXUWd0ZDd4NTJ3ZDZBY3ZQU1BfYWVpV0UxZjdVZTVUbThEZjZDRTR0ZDZDbHpnaGhHeVpDVC05dmdwb0phU2lFMXdGNFRQTEwyNks2UzZSOXJCcDdRUm9WaEFtcnprNXNKWVcwWUFkTkwzNi1FXzFBWUc5TkM3cnoxS1A?oc=5","date":"2025-07-23","type":"regulatory","source":"Business Wire","summary":"Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies - Business Wire","headline":"Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNV1c1OEhDZGZKV3ZLVG01bUlUU0dpRlhldHNIQ08tSVdZSGo5RTBPRjNDdUZ3amtSTmt1U2tybi1mUWI4TVZlRVFBektTTWkxd3dySVdvM3E3MHZtd3NxY0IwRF94Z0VaclBmLURKUzlJcXlWdXp3N1V0NHI2aFlvTFlYTGlPSVBmMGx3dzA3Q2F6bUlINU9xUWJnenFteVFpSm0xRWh5RWoweFEtb3Q4MUZ3a0pHTno4YWtIZmxITGJ0MWh2WTY1VXlR?oc=5","date":"2023-07-24","type":"pipeline","source":"PharmTech.com","summary":"Crossbow Therapeutics Debuts with $80 Million in Series A Financing to Advance Antibody Therapeutics - PharmTech.com","headline":"Crossbow Therapeutics Debuts with $80 Million in Series A Financing to Advance Antibody Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOU0ltcWFSS0JXSEVYNk0yQ2pNZnliRmtiM2N5RVBIQ0huVDRLSm1WYlRIMFZ3NHdQZ3U5dHdZNmNTWVdqZ3N1TFN2VkstY2ZEdDJ2R29oZnNObzVTSEpsd3JqRGlYMkVNaGhPTkt4cUNyM0F0bTltZlpDUThIbkg2RzNiOFdITUxxZHc?oc=5","date":"2023-07-12","type":"pipeline","source":"Labiotech.eu","summary":"Crossbow Therapeutics launches with $80M to target cancer - Labiotech.eu","headline":"Crossbow Therapeutics launches with $80M to target cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPY2ZNRFM5UHluLWE5cjRoeUFBcnkzUkRrQ3ZVYWtJS2ZKeUNNY3J5cFY5b2pDbF9nOU9iN2FkZmkwSERERWpPd1VnUFpNS2ZDaGpvS0NBQW5MTWVSWlJLcW1DTUxnM3U5RWg0UlhYZUlhRWVXWUNZLWlRYTVtVVhoRDZfelllb1dlTGtZMm9kNWFTcHFPVWlGNjNDdXpkbXVvSndn?oc=5","date":"2023-07-11","type":"pipeline","source":"The Business Journals","summary":"Pfizer, Lilly back startup headed by former AstraZeneca chief medical officer - The Business Journals","headline":"Pfizer, Lilly back startup headed by former AstraZeneca chief medical officer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}